C horoid plexus tumors (CPTs) account for 1%-4% of all brain neoplasms in the pediatric age group and 13% of brain tumors occurring in the 1st year of life.
cisterns, on the surface of both cerebral hemispheres, and along the spinal cord ( Fig. 1A-C ).
Operation
The tumor was surgically treated via interhemispheric transcallosal approach. However, because of intraoperative bleeding, tumor removal was limited to a partial resection. Both lumbar and ventricular cerebrospinal fluid (CSF) collections were negative for neoplastic cells.
Pathological Findings
Neuropathological examination showed a papillary CPT with large areas of necrosis, without nuclear pleomorphism. Three mitoses per 10 randomly selected high-power fields were found. The Ki-67 proliferation index was 9%. Brain invasion was not found. The diagnosis was ACPP.
Second Operation and Postoperative Course
Two weeks after the initial resection, residual tumor was completely removed via a left frontal transcortical approach. One week later, postoperative MRI was performed as staging before the start of chemotherapy, which was considered given the presence of leptomeningeal enhancement on the preoperative scan. Magnetic resonance imaging confirmed gross-total removal and showed a reduction in leptomeningeal intracranial involvement ( Fig.  1D and E) . Strict MRI follow-up was then planned and no chemotherapy treatment was adopted. One month later, MRI demonstrated almost complete resolution of the intracranial and spinal leptomeningeal enhancement ( Fig.  1F-H) , which was no longer visible on a subsequent MRI performed 5 months later. The patient is still disease free 26 months after surgery ( Fig. 1I and J).
Case 2

History and Examination
An 11-month-old boy was referred to our hospital because of macrocephaly. Neurological examination and funduscopy were normal. Brain MRI showed a large, left intraventricular, polylobulated contrast-enhancing mass originating from the choroid glomus and extending into the ipsilateral temporal and occipital horns ( Fig. 2A-C) . No parenchymal infiltration was evident. Diffuse leptomeningeal enhancement was demonstrated into the basal cisterns and along the brainstem.
Operation
A left temporoparietal craniectomy was performed and gross-total tumor removal was achieved. Cerebrospinal fluid collections from lumbar puncture and ventricles were negative.
Pathological Findings
Neuropathological examination showed a papillary CPT with small areas of necrosis, without nuclear pleomorphism. Three mitoses per 10 randomly selected highpower fields were found. The Ki-67 proliferation index was 7%. Brain invasion was not found. 
Postoperative Course
Magnetic resonance imaging performed 3 weeks after surgery (Fig. 2D-F) did not show residual disease and demonstrated also almost complete resolution of the leptomeningeal enhancement, which was no longer visible on subsequent MRI performed 1 month later. However, surveillance neuroimaging performed at 12 months revealed a small, growing, contrast-enhancing lesion located along the posterior margin of the surgical cavity (Fig. 2G) . The nodule was surgically removed. No neoplastic cells were found in the ventricular CSF samples. The diagnosis of ACPP was confirmed. Two months later, MRI showed no residual disease and no signs of leptomeningeal involvement. Chemotherapy was never administered and the patient is still disease free 43 months after the first surgery ( Fig. 2H and I ).
Discussion
Choroid plexus papillomas metastasize as intraparenchymal or intraventricular nodules, especially subarachnoid nodules, or less frequently as diffuse leptomeningeal seeding. 1, 2, [4] [5] [6] 8, 12, 13, 15 Metastases at diagnosis in cases of ACPP are not uncommon and have been reported in 17% of cases according to the Choroid Plexus Tumor-Society of Pediatric Oncology-2000 (CPT-SIOP-2000) study of CPTs. 17 In cases of metastases, local recurrence, or incomplete resection, chemotherapy is recommended and the pa- tient should be evaluated for a second-look surgery thereafter. 3, 11 Radiation therapy has also been used in combination with chemotherapy in metastatic ACPP patients. 3, 11 Cases in the present report demonstrated diffuse, pathological leptomeningeal contrast enhancement on baseline MRI, strongly suspicious for arachnoidal infiltration and seeding, progressively and completely vanishing after surgical removal of the primary tumor. Similar observations have been reported in the literature but they involved adults with CPP. 6, 16 To our knowledge, this phenomenon has never been described in ACPP and in children.
In our cases, the interval between surgery and complete disappearance of the leptomeningeal enhancement was a few months, with rapid evidence of a reduction in contrast enhancement on the earlier postoperative MRI studies performed 1 week after the second surgery in the first case and 3 weeks after surgery in the second case. This decrease in enhancement was the rationale behind the decision to adopt a "wait and see" approach with close neuroimaging and clinical monitoring and to avoid adjuvant chemotherapy. In the second child, a local recurrence occurred probably as a result of the growth of a microresidual component along the resection margins, without any MRI sign of arachnoidal involvement. After surgical removal of the lesion, the same follow-up strategy was adopted and no adjuvant therapy was started. No signs of local recurrence or dissemination appeared in subsequent MRI.
Regarding the nature of the leptomeningeal enhancement, it has been supposed that it could be the result of abnormal arachnoidal vessel permeability triggered by hormonal factors (such as vascular endothelial growth factor) secreted by the tumor or of real arachnoidal infiltration by a lining of neoplastic cells, depending on a critical concentration of growth factors secreted by the tumor.
6,16
The removal of primary tumor and thus the lack of a triggering factor may explain the resolution of leptomeningeal enhancement. At the same time, we recognize that leptomeningeal enhancement does not necessarily mean malignant seeding since it has been described in cases of obstructive hydrocephalus (venous stasis) or of leptomeningeal irritation from postoperative subarachnoid bleeding in children with brain tumors. 16 The latter does not apply in our patients since leptomeningeal enhancement was demonstrated before any surgical procedure.
Regardless of the true cause, MRI evaluation is standard in the determination of secondary dissemination in brain malignancies, and the neuro-oncological strategy depends on MRI data even without histological confirmation. In our cases, given the location of the leptomeningeal involvement (basal cisterns and spine), an additional surgical procedure would have been necessary to evaluate the nature of the contrast enhancement, exposing the children to additional risks; therefore, close MRI follow-up was the preferred strategy. Since postoperative chemotherapy is the recommended first-line treatment for ACPP in cases of disseminated disease, MRI evidence of diffuse leptomeningeal contrast enhancement at presentation in ACPP cases should be interpreted with caution, and restaging should be performed after gross-total removal or subtotal removal of the tumor. Indeed, leptomeningeal enhancement in the setting of ACPP may represent a tumor-related effect rather than true tumor dissemination. In conclusion, our observations expand our knowledge about the natural history and biological behavior of ACPP and highlight the role of close clinical and neuroimaging monitoring in the management of ACPP with MRI evidence of leptomeningeal involvement at presentation.
